Abstract
This research describes how the FDA has incorporated risk analysis methodology into its inspection of pharmaceutical manufacturers in the time period between 2004-2008. It analyzes the violations specified in FDA warning letters that are issued after site inspections of pharmaceutical facilities. The outcome of this analysis is to evaluate the FDA’s performance to determine whether it has improved the overall inspection process and increased its quality assurance
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
